Haematologica Reports 2005; 1: issue 8
New Drugs in Hematology

Corporate Symposium

Thalassemia: the Continued Challenge
Nathan DG

Deferasirox (ICL670): from bench to bedside
Alberti D

ICL670: clinical outcome
Cappellini MD

Treatment of aggressive lymphoma
Gisselbrecht C, Mounier N

Gemtuzumab ozogamicin
Amadori S

Imatinib – an overview
Deininger MWN

SKI-606 and Beyond
Boschelli DH, Boschelli F, Wu B, Ye F, Wang Y, Golas JM, Young T, Lucas J

Follicular Lymphomas
Solal-Celigny P

Anti-CD80 Monoclonal Antibody: Galiximab
Czuczman MS

CD30: a suitable target for immunotherapy?
Borchmann P

Palifermin (Kepivance™) in the treatment of mucositis
Emmanouilides C

Combinations of Biological Agents in Non-Hodgkin’s Lymphomas
Cheson BD

Chronic lymphocytic leukemia
Gentile M, Guarini A, Mauro FR, Foà R

Bcr-abl peptides for chronic myeloid leukemia
Bocchia M, Ippoliti M, Pirrotta MT, Abruzzese E, Trawinska MM, Forconi F, Gozzetti A, Raspadori D, Lauria F

Tumor idyotipe as target antigen for multiple myeloma
Curti A

Augmenting anti-tumor efficacy of adoptive immunotherapy with Marrow Infiltrating Lymphocytes
Borrello I

Bortezomib therapy for Refractory/Relapsed Multiple Myeloma
Cavo M

Ubiquitin-proteasome system is a sensitive target in ph+ leukemia
Martinelli G, Cilloni D, Rosti G, Piccaluga P, Rondoni M, Bosi C, Paolini S, Pane F, Soverini S, Amabile M, Nadali G, Izzo B, Iacobucci I, Poerio S, Terragna C, Ottaviani E,
Grafone T, De Vivo A, Testoni N, Saglio G, Baccarani M

Bortezomib in lymphoma
Goy A

Beyond bortezomib alone: Combination therapy and new strategies in targeting the proteasome
Richardson PG

Thalidomide analogs
Tosi P, Zamagni E , Cangini D, Tacchetti P, Perrone G, Ceccolini M, Cavo M

Tipifarnib in hematological malignancies
Harousseau J-L

Direct and indirect antitumor activity of zoledronic acid
Massaia M, Mariani S , Pantaleoni F, Muraro M, Peola S, Hwang SY, Castella B, Matta G, Foglietta M, Fiore F, Coscia M, Boccadoro M

MLN518 – an overview
Deininger MWN

Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies
Bhalla K

Clinical experience with intravenous and oral formulations of the novel histone deacetylase
inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies

O’Connor OA

Anti-Tumor Activity of CCI-779 in Relapsed Mantle Cell Lymphoma
Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH, Witzig TE

Gemcitabine: from solid tumor to hematology
Zinzani PL, Tani M, Stefoni V , Marchi E, Fina M, Alinari L

The Developing Role of Clofarabine in Acute Leukemias
Faderl S

Oral fludarabine
Verhoef GEG

Oxaliplatin in lymphoma
Haioun C, Mondor CH

Lymphomatous meningitis
Hatton C


 

©2006 Ferrata Storti Foundation